摘要
血管内物质侵入到脑中细胞外间隙,通过无血脑屏障(BBB)位点的内皮细胞并不仅移转脑脊髓液(CSF)还有与非-BBB位点毗邻的脑软细胞组织中的间隙液体(ISF)。很可能CSF可以通过蛛网膜绒毛和颗粒直接排进血液,同样由脑中的蛛网膜下腔和淋巴管进入淋巴结。然而,ISF通过沿毛细血管和动脉通路进入到颈部淋巴结。按照提出的流动路径,似乎对维持正常的脑部功能是有害的,可以合理的推断阻塞流体的这些路径有可能诱导一些脑部的功能素乱,例如阿尔治海默氏病。根据这些假设的通路去消除脑中的β-淀粉样蛋白,神经中主要的β-淀粉样蛋白多肽可被肽酶降解,由脑实质流出进入血液通过外向转移体定位于脑血管,通过血管周围的通路排出进入颈部淋巴结,或者被其他类型的脑部细胞占用。对于血管周通路,ISF包括β-淀粉样蛋白多肽扩散到脑实质细胞外间隙,进入毛细血管基底膜,进入到动脉被囊介质,并排除脑部。这篇综述中,阐述了这些用于清除包括β-淀粉样蛋白在内的流体从脑部进入血液的通路,并简单讨论了这些通路异常和脑疾病之间的关系。
关键词: β-淀粉样蛋白,血脑屏障,脑脊髓液,间隙液体,血管周排放。
Current Medicinal Chemistry
Title:Clearance of Beta-Amyloid in the Brain
Volume: 21 Issue: 35
Author(s): Masaki Ueno, Yoichi Chiba, Koichi Matsumoto, Toshitaka Nakagawa and Hiroshi Miyanaka
Affiliation:
关键词: β-淀粉样蛋白,血脑屏障,脑脊髓液,间隙液体,血管周排放。
摘要: Intravascular substances invade extracellular spaces in the brain via endothelial cells in the sites without bloodbrain barrier (BBB) and move not only in the cerebrospinal fluid (CSF) but also in the interstitial fluid (ISF) of brain parenchyma adjacent to non-BBB sites. It is likely that CSF drains directly into the blood via arachnoid villi and granulations and also to lymph nodes via subarachnoid spaces in the brain and nasal lymphatics, whereas ISF drains to cervical lymph nodes through pathways along vascular wall of capillaries and arteries. As the supposed pathways of fluids seem to be critical for the maintenance of normal brain function, it is reasonable to suspect that an obstacle to the passage of fluids through these pathways likely induces some kinds of brain dysfunction such as Alzheimer’s disease. According to assumed pathways for the elimination of amyloid-β (Aβ) from the brain, Aβ peptides produced mainly in neurons are degraded by peptidases, flow out of the brain parenchyma into the blood through efflux transporters located in cerebral vessels, drain through perivascular pathways into the cervical lymph nodes, or are taken up by some kinds of cells in the brain. As for the perivascular pathways, ISF including Aβ peptides diffuses in the extracellular spaces of the brain parenchyma, enters basement membranes of capillaries, passes into the tunica media of arteries, and drains out of the brain. In this review, these pathways for the clearance of fluids including Aβ from the brain into the blood are briefly reviewed and the relationship between dysfunction of these pathways and brain diseases is discussed.
Export Options
About this article
Cite this article as:
Ueno Masaki, Chiba Yoichi, Matsumoto Koichi, Nakagawa Toshitaka and Miyanaka Hiroshi, Clearance of Beta-Amyloid in the Brain, Current Medicinal Chemistry 2014; 21 (35) . https://dx.doi.org/10.2174/0929867321666141011194256
DOI https://dx.doi.org/10.2174/0929867321666141011194256 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Allergy and Inflammation: An Immunological and Therapeutic Approach
Recent Patents on Inflammation & Allergy Drug Discovery Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry HIV Compartmentalization: A Review on a Clinically Important Phenomenon
Current HIV Research Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents Wzy-Dependent Bacterial Capsules as Potential Drug Targets
Current Drug Targets Synthesis and Biological Activities of New Halophenols
Medicinal Chemistry Editorial [Revisiting the Paris Declaration: Pharmacogenomics and Personalized Medicine as Accelerators for Development Aid and Effectiveness]
Current Pharmacogenomics and Personalized Medicine The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Editorial [Hot topic:Targeted Alpha Particle Therapy (Guest Editors: Ganesan Vaidyanathan and Roy Larsen)]
Current Radiopharmaceuticals Intestinal Parasite Infestation in HIV Infected Patients
Current HIV Research The Potential Dual Effects of Anesthetic Isoflurane on Aβ-Induced Apoptosis
Current Alzheimer Research Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer
Current Cancer Drug Targets Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design Redox State, Oxidative Stress, and Molecular Mechanisms of Protective and Toxic Effects of Bilirubin on Cells
Current Pharmaceutical Design Progression of Alzheimer-type Neurofibrillary Tangles is Related to the Proximodistal Segments of the Hemispheric Arteries
Current Alzheimer Research Substance P in Rheumatic Diseases
Current Rheumatology Reviews Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Infectious Disorders - Drug Targets New Developments in Vaccines, Inhibitors of Anthrax Toxins, and Antibiotic Therapeutics for Bacillus anthracis
Current Medicinal Chemistry The Use of Proteomics to Study Infectious Diseases
Infectious Disorders - Drug Targets